血浆源性蛋白和成像生物标志物可区分眼咽肌营养不良症的疾病严重程度。

IF 3.4 4区 医学 Q2 CLINICAL NEUROLOGY
Journal of neuromuscular diseases Pub Date : 2025-03-01 Epub Date: 2024-12-20 DOI:10.1177/22143602241304990
Ian C Smith, Marcos L Sampaio, Gerd Melkus, Kaitlynn Meier-Ross, Shaoni Chakraborty, Cameron Stotts, Pierre R Bourque, Hanns Lochmuller, Bernard Brais, Othmane Ayoub, Theodore J Perkins, Mireille Khacho, Jodi Warman-Chardon
{"title":"血浆源性蛋白和成像生物标志物可区分眼咽肌营养不良症的疾病严重程度。","authors":"Ian C Smith, Marcos L Sampaio, Gerd Melkus, Kaitlynn Meier-Ross, Shaoni Chakraborty, Cameron Stotts, Pierre R Bourque, Hanns Lochmuller, Bernard Brais, Othmane Ayoub, Theodore J Perkins, Mireille Khacho, Jodi Warman-Chardon","doi":"10.1177/22143602241304990","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, slowly progressive neuromuscular disorder characterized by ptosis, dysphagia, and proximal limb weakness. Emerging clinical trials require rapidly accessible and sensitive biomarkers to evaluate OPMD disease progression and potential response to future treatments.</p><p><strong>Objective: </strong>This cross-sectional study was designed to identify candidate circulating protein and imaging biomarkers of OPMD severity for future use in clinical trials.</p><p><strong>Methods: </strong>Twenty-five individuals with OPMD (age 63.3 ± 10.5 years; GCN copy number of 13 in <i>PABPN1</i>) were assessed using the 7k SOMAScan assay to profile the plasma proteome, and MRI to quantify replacement of muscle by fat. OPMD severity was first categorized using the clinical presence/absence of limb weakness, and protein signals were considered distinguishing if they differed by more than 30% between subgroups and had statistically significant <i>P</i>-values after correcting for multiple comparisons. Distinguishing proteins were contrasted with age-matched controls (<i>n </i>= 10). OPMD severity was also treated as a continuous variable using fat fraction of the soleus muscle, and proteins were considered distinguishing if the slope of relationship between protein signal and soleus fat fraction differed significantly from zero after correcting for multiple comparisons. Pathway analyses were conducted using Metascape and the Database for Annotation, Visualization, and Integrated Discovery webtools.</p><p><strong>Results: </strong>Eighteen plasma proteins distinguished OPMD on both indicators of severity. Pathway analyses identified skeletal muscle tissue, phagocytosis/engulfment, and extracellular matrix organization as enriched ontology clusters in OPMD with limb weakness. The most distinguishing plasma protein signals (ACTN2, MYOM2, CA3, APOBEC2, MYL3, and PDLIM3) were over 200% higher in OPMD with limb weakness than OPMD without limb weakness as well as controls, and correlated strongly with percent of fatty replacement of soleus (<i>r </i>= 0.89 ± 0.04).</p><p><strong>Conclusions: </strong>The candidate biomarkers identified contribute to the ongoing search for sensitive and accessible biomarkers of OPMD progression, prognosis, and monitoring.</p>","PeriodicalId":16536,"journal":{"name":"Journal of neuromuscular diseases","volume":" ","pages":"244-259"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy.\",\"authors\":\"Ian C Smith, Marcos L Sampaio, Gerd Melkus, Kaitlynn Meier-Ross, Shaoni Chakraborty, Cameron Stotts, Pierre R Bourque, Hanns Lochmuller, Bernard Brais, Othmane Ayoub, Theodore J Perkins, Mireille Khacho, Jodi Warman-Chardon\",\"doi\":\"10.1177/22143602241304990\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, slowly progressive neuromuscular disorder characterized by ptosis, dysphagia, and proximal limb weakness. Emerging clinical trials require rapidly accessible and sensitive biomarkers to evaluate OPMD disease progression and potential response to future treatments.</p><p><strong>Objective: </strong>This cross-sectional study was designed to identify candidate circulating protein and imaging biomarkers of OPMD severity for future use in clinical trials.</p><p><strong>Methods: </strong>Twenty-five individuals with OPMD (age 63.3 ± 10.5 years; GCN copy number of 13 in <i>PABPN1</i>) were assessed using the 7k SOMAScan assay to profile the plasma proteome, and MRI to quantify replacement of muscle by fat. OPMD severity was first categorized using the clinical presence/absence of limb weakness, and protein signals were considered distinguishing if they differed by more than 30% between subgroups and had statistically significant <i>P</i>-values after correcting for multiple comparisons. Distinguishing proteins were contrasted with age-matched controls (<i>n </i>= 10). OPMD severity was also treated as a continuous variable using fat fraction of the soleus muscle, and proteins were considered distinguishing if the slope of relationship between protein signal and soleus fat fraction differed significantly from zero after correcting for multiple comparisons. Pathway analyses were conducted using Metascape and the Database for Annotation, Visualization, and Integrated Discovery webtools.</p><p><strong>Results: </strong>Eighteen plasma proteins distinguished OPMD on both indicators of severity. Pathway analyses identified skeletal muscle tissue, phagocytosis/engulfment, and extracellular matrix organization as enriched ontology clusters in OPMD with limb weakness. The most distinguishing plasma protein signals (ACTN2, MYOM2, CA3, APOBEC2, MYL3, and PDLIM3) were over 200% higher in OPMD with limb weakness than OPMD without limb weakness as well as controls, and correlated strongly with percent of fatty replacement of soleus (<i>r </i>= 0.89 ± 0.04).</p><p><strong>Conclusions: </strong>The candidate biomarkers identified contribute to the ongoing search for sensitive and accessible biomarkers of OPMD progression, prognosis, and monitoring.</p>\",\"PeriodicalId\":16536,\"journal\":{\"name\":\"Journal of neuromuscular diseases\",\"volume\":\" \",\"pages\":\"244-259\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of neuromuscular diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/22143602241304990\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/12/20 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of neuromuscular diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/22143602241304990","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/20 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:眼咽肌营养不良症(OPMD)是一种罕见的、晚发的、缓慢进展的神经肌肉疾病,其特征为上睑下垂、吞咽困难和近端肢体无力。新兴的临床试验需要快速获取和敏感的生物标志物来评估OPMD疾病进展和对未来治疗的潜在反应。目的:本横断面研究旨在确定候选循环蛋白和OPMD严重程度的成像生物标志物,用于未来的临床试验。方法:25例OPMD患者(年龄63.3±10.5岁;GCN拷贝数(PABPN1中的13)使用7k SOMAScan测定来分析血浆蛋白质组,并使用MRI来量化脂肪替代肌肉。OPMD的严重程度首先根据临床是否存在肢体无力进行分类,如果蛋白质信号在亚组之间的差异超过30%,并且在校正多重比较后具有统计学意义的p值,则认为可以区分。区分蛋白与年龄匹配对照(n = 10)。OPMD严重程度也被视为比目鱼肌脂肪分数的连续变量,并考虑蛋白质,以区分蛋白质信号与比目鱼肌脂肪分数之间的关系斜率在多次比较校正后是否显著不同于零。路径分析使用metscape和数据库进行注释、可视化和集成发现网络工具。结果:18种血浆蛋白在两种严重程度指标上区分OPMD。通路分析发现,骨骼肌组织、吞噬/吞噬和细胞外基质组织是肢体无力的OPMD中丰富的本体集群。最显著的血浆蛋白信号(ACTN2、MYOM2、CA3、APOBEC2、MYL3和PDLIM3)在有肢体无力的OPMD中比无肢体无力的OPMD和对照组高200%以上,且与比目鱼肌脂肪替代率密切相关(r = 0.89±0.04)。结论:确定的候选生物标志物有助于持续寻找OPMD进展、预后和监测的敏感和可获取的生物标志物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Plasma-derived protein and imaging biomarkers distinguish disease severity in oculopharyngeal muscular dystrophy.

Background: Oculopharyngeal muscular dystrophy (OPMD) is a rare, late-onset, slowly progressive neuromuscular disorder characterized by ptosis, dysphagia, and proximal limb weakness. Emerging clinical trials require rapidly accessible and sensitive biomarkers to evaluate OPMD disease progression and potential response to future treatments.

Objective: This cross-sectional study was designed to identify candidate circulating protein and imaging biomarkers of OPMD severity for future use in clinical trials.

Methods: Twenty-five individuals with OPMD (age 63.3 ± 10.5 years; GCN copy number of 13 in PABPN1) were assessed using the 7k SOMAScan assay to profile the plasma proteome, and MRI to quantify replacement of muscle by fat. OPMD severity was first categorized using the clinical presence/absence of limb weakness, and protein signals were considered distinguishing if they differed by more than 30% between subgroups and had statistically significant P-values after correcting for multiple comparisons. Distinguishing proteins were contrasted with age-matched controls (n = 10). OPMD severity was also treated as a continuous variable using fat fraction of the soleus muscle, and proteins were considered distinguishing if the slope of relationship between protein signal and soleus fat fraction differed significantly from zero after correcting for multiple comparisons. Pathway analyses were conducted using Metascape and the Database for Annotation, Visualization, and Integrated Discovery webtools.

Results: Eighteen plasma proteins distinguished OPMD on both indicators of severity. Pathway analyses identified skeletal muscle tissue, phagocytosis/engulfment, and extracellular matrix organization as enriched ontology clusters in OPMD with limb weakness. The most distinguishing plasma protein signals (ACTN2, MYOM2, CA3, APOBEC2, MYL3, and PDLIM3) were over 200% higher in OPMD with limb weakness than OPMD without limb weakness as well as controls, and correlated strongly with percent of fatty replacement of soleus (r = 0.89 ± 0.04).

Conclusions: The candidate biomarkers identified contribute to the ongoing search for sensitive and accessible biomarkers of OPMD progression, prognosis, and monitoring.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of neuromuscular diseases
Journal of neuromuscular diseases Medicine-Neurology (clinical)
CiteScore
5.10
自引率
6.10%
发文量
102
期刊介绍: The Journal of Neuromuscular Diseases aims to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular diseases (including muscular dystrophy, myasthenia gravis, spinal muscular atrophy, neuropathies, myopathies, myotonias and myositis). The journal publishes research reports, reviews, short communications, letters-to-the-editor, and will consider research that has negative findings. The journal is dedicated to providing an open forum for original research in basic science, translational and clinical research that will improve our fundamental understanding and lead to effective treatments of neuromuscular diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信